Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnOrphan Medicine

Aliqopa(copanlisib dihydrochloride)

Lymphoma, B-Cell, Marginal Zone

Marketing Authorisation Holder: Bayer AG

INN: copanlisib

Indication

Treatment of adult patients with relapsed marginal zone lymphoma

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Aliqopa — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.